Aprogen Biologics Inc.

A003060

KR7003060001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
1,047 ^KRW	-5.68%		-19.46%	-63.90%

07-04	Aprogen Biologics Inc. announced that it expects to receive KRW 30.000000384 billion in funding from Aprogen Medicines Inc.	CI
03-13	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aprogen Biologics Inc. announced that it expects to receive KRW 30.000000384 billion in funding from Aprogen Medicines Inc.

July 03, 2024

Aprogen Biologics Inc. announced a private placement to issue 33,039,648 common shares at an issue price of KRW 908 per share for the gross proceeds of KRW 30,000,000,384 on July 4, 2024. The transaction will include participation from new returning Aprogen Medicines. The transaction has been approved by shareholders of company, restricted to a hold period and is expected to close on August 14, 2024.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	APROGEN MEDICINES INC.	1,497 KRW	-4.47%	+0.94%	278M
	APROGEN BIOLOGICS INC.	1,047 KRW	-5.68%	-19.46%	99.4M

Latest news about Aprogen Biologics Inc.

Aprogen Biologics Inc. announced that it expects to receive KRW 30.000000384 billion in funding from Aprogen Medicines Inc.	07-03	CI
Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Aprogen Biologics Inc.(KOSE:A003060) dropped from S&P Global BMI Index	18/09/23	CI
Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Aprogen Biologics Inc. announced that it has received KRW 20 billion in funding from Aprogen, Inc.	23/04/23	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 20 billion in funding from Aprogen, Inc.	20/04/23	CI
Aprogen Biologics Inc. announced that it has received KRW 40 billion in funding	13/04/23	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 40 billion in funding	12/04/23	CI
Aprogen Biologics Inc. announced that it has received KRW 40.0000005 billion in funding from Aprogen Medicines Inc.	11/04/23	CI
Aprogen pharmaceuticals,Inc. completed the acquisition of Aprogen Biologics Inc. from Aprogen, Inc.	30/12/22	CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
Aprogen Pharmaceuticals to Raise $35.1 Million Through Stock Issuance	04/10/22	MT
Aprogen pharmaceuticals,Inc. agreed to acquire Aprogen Biologics Inc. from Aprogen, Inc.	03/10/22	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 50 billion in funding from Aprogen Medicines Inc.	03/10/22	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	14/03/22	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/11/21	CI
Aprogen Medicines Inc. announced that it expects to receive KRW 105 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd., Aprogen pharmaceuticals,Inc., Aprogen Healthcare & Games Inc.	15/09/21	CI
Immunotech Biopharm : Hires Aprogen Director as New Tech Chief	14/04/21	MT
Aprogen KIC Inc. cancelled the acquisition of additional 5.6% stake in Aprogen pharmaceuticals,Inc..	13/01/21	CI
Aprogen KIC Inc. agreed to acquire additional 5.6% stake in Aprogen pharmaceuticals,Inc. for KRW 17.8 billion.	13/01/20	CI
Aprogen pharmaceuticals,Inc. acquired an additional 6.38% stake in Locojoy International Corporation from Aprogen Biologics Inc. for KRW 7 billion.	29/09/19	CI

Chart Aprogen Biologics Inc.

Duration

Period

More charts

Company Profile

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
APROGEN BIOLOGICS INC.	-63.90%	99.4M
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+33.88%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+11.33%	234B
NOVARTIS AG	+15.41%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals